Dempski, Robert E.
University of Massachusetts Medical Center
University of Massachusetts Medical School
Hepatitis C virus (HCV) infection can cause serious liver disease. Efforts to eliminate the virus involve the development of novel drugs designed to disrupt viral replication. One of the ways to inhibit the virus is by targeting the HCV enzyme NS3/4A protease. MK-5172 is a potent protease inhibitor recently approved by the FDA for the treatment of HCV. As part of this project, I synthesized four new analogues of MK-5172. These analogues, which lack the methoxy group on the quinoxaline, are either linear or have different macrocyclization than MK-5172. The compounds were tested for enzyme inhibitory activity using kinetic assays. The new macrocyclic analogues show potent inhibitory activity against wild-type NS3/4A protease and the D168A drug resistant variant.
Worcester Polytechnic Institute
Major Qualifying Project
Access to this report is limited to members of the WPI community. Please contact a project advisor or their department to request access
Restricted-WPI community only
Chemistry and Biochemistry
Your accessibility may vary due to other restrictions.